Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Regenacy Pharmaceuticals, Inc.”

13 pharma patents match "Regenacy Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 13
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 13 pharmaceutical patents matching "Regenacy Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

13 results for “Regenacy Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11702389

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted
  2. US 11542242

    Substituted piperazines as selective HDAC1,2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  3. US 10968180

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  4. US 10858323

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Regenacy Pharmaceuticals, Inc. · Granted Dec 8, 2020 · Expires Dec 3, 2040

    granted
  5. US 10774056

    Substituted piperazines as selective HDAC1,2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Sep 15, 2020 · Expires Sep 10, 2040

    granted
  6. US 10385031

    Substituted piperazines as selective HDAC1,2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Aug 20, 2019 · Expires Aug 15, 2039

    granted
  7. US 10358421

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted
  8. US 10239837

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  9. US 10125131

    Selective HDAC3 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  10. US 10040769

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Regenacy Pharmaceuticals, Inc. · Granted Aug 7, 2018 · Expires Aug 2, 2038

    granted
  11. US 9957259

    Selective HDAC1 and HDAC2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted May 1, 2018 · Expires Apr 26, 2038

    granted
  12. US 9790180

    Piperidine derivatives as HDAC1/2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Oct 17, 2017 · Expires Oct 12, 2037

    granted
  13. US 9765066

    Selective HDAC1 and HDAC2 inhibitors

    Regenacy Pharmaceuticals, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted